JP2011041526A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011041526A5 JP2011041526A5 JP2009192615A JP2009192615A JP2011041526A5 JP 2011041526 A5 JP2011041526 A5 JP 2011041526A5 JP 2009192615 A JP2009192615 A JP 2009192615A JP 2009192615 A JP2009192615 A JP 2009192615A JP 2011041526 A5 JP2011041526 A5 JP 2011041526A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- oligonucleotide
- sequence listing
- genotype
- determining
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims 18
- 239000000523 sample Substances 0.000 claims 13
- 208000005176 Hepatitis C Diseases 0.000 claims 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 238000010998 test method Methods 0.000 claims 6
- 230000001225 therapeutic effect Effects 0.000 claims 6
- 238000007689 inspection Methods 0.000 claims 4
- 102000014150 Interferons Human genes 0.000 claims 3
- 108010050904 Interferons Proteins 0.000 claims 3
- 230000000692 anti-sense effect Effects 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 229940079322 interferon Drugs 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 239000003550 marker Substances 0.000 claims 2
- 230000003321 amplification Effects 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009192615A JP5727694B2 (ja) | 2009-08-21 | 2009-08-21 | Ｃ型肝炎の治療効果を予測するためのマーカー及びｃ型肝炎の治療効果の予測を行う方法並びにｃ型肝炎の予防又は治療剤 |
| PCT/JP2010/063262 WO2011021508A1 (ja) | 2009-08-21 | 2010-08-05 | Ｃ型肝炎の治療効果を予測するためのマーカー及びｃ型肝炎の治療効果の予測を行う方法並びにｃ型肝炎の予防又は治療剤 |
| CN2010800365956A CN102482664A (zh) | 2009-08-21 | 2010-08-05 | 用于预测c型肝炎的治疗效果的标记物和预测c型肝炎的治疗效果的方法以及c型肝炎的预防或治疗剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009192615A JP5727694B2 (ja) | 2009-08-21 | 2009-08-21 | Ｃ型肝炎の治療効果を予測するためのマーカー及びｃ型肝炎の治療効果の予測を行う方法並びにｃ型肝炎の予防又は治療剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011041526A JP2011041526A (ja) | 2011-03-03 |
| JP2011041526A5 true JP2011041526A5 (enExample) | 2013-07-18 |
| JP5727694B2 JP5727694B2 (ja) | 2015-06-03 |
Family
ID=43606963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009192615A Active JP5727694B2 (ja) | 2009-08-21 | 2009-08-21 | Ｃ型肝炎の治療効果を予測するためのマーカー及びｃ型肝炎の治療効果の予測を行う方法並びにｃ型肝炎の予防又は治療剤 |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP5727694B2 (enExample) |
| CN (1) | CN102482664A (enExample) |
| WO (1) | WO2011021508A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5656159B2 (ja) * | 2009-08-24 | 2015-01-21 | 独立行政法人理化学研究所 | インターフェロン療法の効果予測用マーカー |
| JP5787337B2 (ja) * | 2010-03-19 | 2015-09-30 | 公益財団法人ヒューマンサイエンス振興財団 | Ｃ型肝炎の治療効果を予測するためのマーカー群、検査方法及び検査用キット |
| JP2014509628A (ja) * | 2011-03-31 | 2014-04-21 | ノバルティス アーゲー | Ｃ型肝炎ウイルス感染症を治療するためのアリスポリビル |
| CN103074417B (zh) * | 2012-06-20 | 2015-06-24 | 宁波海尔施基因科技有限公司 | 一种丙型肝炎治疗用药指导的多重基因检测方法 |
| CN102816838A (zh) * | 2012-07-06 | 2012-12-12 | 吉林艾迪康医学检验所有限公司 | 用于检测丙型肝炎患者il28b snp12980275多态性的试剂盒 |
| WO2014157377A1 (ja) | 2013-03-26 | 2014-10-02 | 株式会社ニッポンジーン | 遺伝子多型の識別に用いるプライマーとプローブのセットおよびその利用 |
| JP6155750B2 (ja) * | 2013-03-27 | 2017-07-05 | 東洋紡株式会社 | ＳＮＰ（ｒｓ１１８８１２２２）を検出するためのプローブ |
-
2009
- 2009-08-21 JP JP2009192615A patent/JP5727694B2/ja active Active
-
2010
- 2010-08-05 CN CN2010800365956A patent/CN102482664A/zh active Pending
- 2010-08-05 WO PCT/JP2010/063262 patent/WO2011021508A1/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Matsuura et al. | Circulating let‐7 levels in plasma and extracellular vesicles correlate with hepatic fibrosis progression in chronic hepatitis C | |
| JP2011041526A5 (enExample) | ||
| JP2010508042A5 (enExample) | ||
| JP2012518421A5 (enExample) | ||
| JP2010515448A5 (enExample) | ||
| JP2009077712A5 (enExample) | ||
| RU2017100015A (ru) | Набор или устройство для обнаружения рака желчных путей и способ обнаружения | |
| JP2016509833A5 (enExample) | ||
| Besse et al. | Genotyping and resistance profile of hepatitis C (HCV) genotypes 1–6 by sequencing the NS3 protease region using a single optimized sensitive method | |
| US8945833B2 (en) | Method for determining drug resistance mutations in any of the non-structural protein regions NS3 to NS5B of hepatitis C virus (HCV) for genotypes 1 to 6 | |
| JP2016533708A5 (enExample) | ||
| CN102277441B (zh) | 一种快速检测IL28B SNP rs12979860多态性的试剂盒 | |
| JPWO2019208671A5 (enExample) | ||
| JP2009518001A5 (enExample) | ||
| JP2010035552A5 (enExample) | ||
| CN107177676A (zh) | 长链非编码rna nonhsat113026用于肾癌诊断分子标志物的用途 | |
| WO2007001310A3 (en) | Methods and compositions for detecting rhinoviruses | |
| JP2014003946A5 (enExample) | ||
| CN103695534B (zh) | 检测dhfr的c829t单核苷酸多态性的引物和方法 | |
| JP2017512204A5 (enExample) | ||
| JP2005528910A5 (enExample) | ||
| TWI531654B (zh) | 用於鑑別ｈ５禽流感病毒病原性之寡核酸探針、含其之套組及方法 | |
| CN104726608B (zh) | VEGFR2基因Val297Ile位点的应用方法 | |
| CN104404044B (zh) | 与心肌梗死易感相关的anril基因外显子区单核苷酸多态位点的检测方法及其应用 | |
| JP2010533497A5 (enExample) |